Trial
NCT00611858
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Bristol-Myers Squibb
Condition
Rectal Cancer
Intervention
Cetuximab
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-08